References
- Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013:368:34–44.
- Gilead. Sofosbuvir for treatment of chronic hepatitis C infection. Antiviral drugs advisory committee meeting briefing document. 25 October 2013. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/antiviraldrugsadvisorycommittee/ucm371877.pdf
- Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004;65: 2335–42.
- Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 2012;19: 601–7.
- Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008;(109):S1–99.
- Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 2008;51:263–77.
- Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, et al. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 2013;159:729–38.
- Bhamidimarri KR, Gutierrez J, Grigorian A, Peyton A, Levy C, O’Brien C, et al. Urgent treatment with sofosbuvir based regimen for hepatitis C genotype 1 patients with severe renal insufficiency (GFR < 30mL/min). Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, November 7–11, 2014.
- Saxena V, Koraishy FM, Sise M, Lim JK, Chung RT, Liapakis A, et al. LP08: safety and efficacy of sofosbuvir- containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-target. J Hepatol 2015;62:S267.
- Peck-Radosavlievic M, Boletis J, Besisik F, Ferraz ML, Alric L, Samuel D, et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol 2011;9:242–8.
- Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, et al. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts. Am J Kidney Dis 2013;62:789–95.
- AASLD/IDSA HCVGuidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932–54.
- Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003;42:631–57.
- Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia, H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:257–63.
- Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, et al. LO1: safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-I study. J Hepatol 2015;62:S257.
- Roth D, Nelson D, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, et al. LPO2: C-surfer: grazprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. J Hepatol 2015;62:S263–4.